Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.95 USD

45.95
9,987,365

+0.59 (1.30%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $45.64 -0.31 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence

    Zacks Equity Research

    LabCorp (LH) at a 52-Week High: What's Driving the Stock?

    by Zacks Equity Research

    LabCorp (LH) banks on Chiltern International Group's buyout. An upbeat guidance boosts investors' confidence.

      Zacks Equity Research

      What's Happening in Advanced Renal Cell Carcinoma Space?

      by Zacks Equity Research

      The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,

        Zacks Equity Research

        Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer

        by Zacks Equity Research

        Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.

          Zacks Equity Research

          AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA

          by Zacks Equity Research

          AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.

            Zacks Equity Research

            Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.

              Zacks Equity Research

              Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA

              by Zacks Equity Research

              Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.

                Arpita Dutt headshot

                Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

                by Arpita Dutt

                This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

                  Zacks Equity Research

                  Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

                  by Zacks Equity Research

                  Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.

                    Zacks Equity Research

                    Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

                    by Zacks Equity Research

                    Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

                      Zacks Equity Research

                      Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success

                      by Zacks Equity Research

                      Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.

                        Zacks Equity Research

                        Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

                        by Zacks Equity Research

                        Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

                          Zacks Equity Research

                          Cancer Space Update: Pfizer's Bavencio Fails in Phase III

                          by Zacks Equity Research

                          The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

                            by Arpita Dutt

                            Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

                              Zacks Equity Research

                              3 Companies Competing to Gain Lead in Ovarian Cancer Market

                              by Zacks Equity Research

                              Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

                                by Arpita Dutt

                                Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

                                  Zacks Equity Research

                                  J&J Seeks Darzalex's Label Expansion in First-Line Setting

                                  by Zacks Equity Research

                                  Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

                                    Zacks Equity Research

                                    Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

                                    by Zacks Equity Research

                                    Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

                                      Zacks Equity Research

                                      Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

                                      by Zacks Equity Research

                                      Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

                                        Zacks Equity Research

                                        LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

                                        by Zacks Equity Research

                                        The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

                                          by Arpita Dutt

                                          Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

                                            Zacks Equity Research

                                            Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

                                            by Zacks Equity Research

                                            Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

                                              Zacks Equity Research

                                              Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

                                              by Zacks Equity Research

                                              Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.

                                                Zacks Equity Research

                                                Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                                                by Zacks Equity Research

                                                Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                                                  Sweta Killa headshot

                                                  Pharma ETFs Down Post Q3 Earnings

                                                  by Sweta Killa

                                                  The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.